Laura Michaelis, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the future of myeloproliferative neoplasm (MPN) therapy and the implications for patients with MPNs. Dr Michaelis explains that more data is expected to be seen from trials investigating novel agents such as IDH-1/2 inhibitors and BCL-2 inhibitors, agents which have already received approval for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia. Dr Michaelis further talks on the prospects of immunotherapy for myelofibrosis and other advanced MPNs. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

свернуть